Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Mallinckrodt
McKesson
Dow
Moodys

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Litigation Details for NOVARTIS AG v. KAPPOS (D.C. 2010)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NOVARTIS AG v. KAPPOS (D.C. 2010)

Docket   Start Trial Date Filed 2010-07-06
Court District Court, District of Columbia Date Terminated 2012-11-15
Cause 35:145 Patent Infringement Assigned To Ellen Segal Huvelle
Jury Demand None Referred To
Parties DANA-FARBER CANCER INSTITUTE; DAVID J. KAPPOS; NOVARTIS AG; NOVARTIS CORPORATION; NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Patents 6,878,721; 7,097,827; 7,423,148; 7,442,388; 7,516,741; 7,576,221; 7,973,031
Attorneys Daniel James Kelly; Mark H. Anania; Scott S. Christie
Firms McCarter and English, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in NOVARTIS AG v. KAPPOS
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in NOVARTIS AG v. KAPPOS

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for NOVARTIS AG v. KAPPOS (D.C. 2010)

Date Filed Document No. Description Snippet Link To Document
2010-07-06 1 Document 1 Filed 07/06/10 Page 2 of 12 6,656,957; 6,878,721; 7,098,325; 7,112,673; 7,265,089; 7,348,353; 7,423,148…each of these patents is summarized in Exhibit A. Patent Term Guarantee ll. The Patent Term Guarantee…on the Novartis Patents 30. Each of the Novartis Patents is an Older lssued Patent. 31. Each of the…Novartis Patents permanently deprived Novartis of patent term for each of the Novartis Patents to which…United States Patent and Tradernark Oft`ice Off`ice of the General Counsel United States Patent and Trademark External link to document
2011-04-08 16 Filed 04/08/11 Page 2 of 16 6,656,957; 6,878,721; 7,098,325; 7,112,673; 7,265,089; 7,348,353; 7,423,148… these patents is summarized in Exhibit A. Patent Term Guarantee 11. The Patent Term Guarantee… Novartis Patents 31. Each of the Novartis Patents is an Older Issued Patent. …Novartis Patents permanently deprived Novartis of patent term for each of the Novartis Patents to which…RCE-Affected Patents further permanently deprived Novartis of patent term for these patents to which they External link to document
2010-07-07 4 of an action regarding patent and/or trademark number(s) 6,656,957; 6,878,721; 7,098,325; 7,112,673; … 12/2/2003 NOVARTIS AG 2 6,878,721 4/12/2005 …KAPPOS Additional Patent Numbers: Patent No. Date of Patent Holder of Patent 7,265,089 … Arlington, VA 22215 PATENT OR DATE OF PATENT … G Other Pleading PATENT OR DATE OF PATENT External link to document
2012-11-15 49 September 2, 2009—U.S. Patent No. 7,576,221—and as the challenge to that patent was not timely filed, …Novartis Patents—U.S. Patent Nos. 7,807,155 (“the ’155 patent”), 7,968,518 (“the ’518 patent”), and 7,973,031…Congress amended the Patent Act by creating patent term adjustments (“PTA”) to extend patent terms in response…to 1994, U.S. patents were granted for a term of seventeen years from the date the patent issued. In 1994…with other countries’ patent terms. However, because the examination of a patent application often takes External link to document
2012-11-15 50 claims with respect to United States Patent Nos. 6,656,957, 6,878,721, 7,081,532, 7,097,827, 7,098,325, … REMANDED to the U.S. Patent & Trademark Office for recalculation of patent term adjustment in a …is further ORDERED that United States Patent Nos. 7,470,792, 7,807,155, 7,968,518, and 7,973,031… 15 November 2012 1:10-cv-01138-ESH Patent None District Court, District External link to document
2013-01-23 61 action regarding patent and/or trademark number(s) 6,656,957; 6,878,721; 7,098,325; …claims with respect to United States Patent Nos. 6,656,957, 6,878,721, 7,081,532, 7,097,827, 7,098,325, …Novartis Patents—U.S. Patent Nos. 7,807,155 (“the ’155 patent”), 7,968,518 (“the ’518 patent”), and 7,973,031…Congress amended the Patent Act by creating patent term adjustments (“PTA”) to extend patent terms in response…None Cause: 35:145 Patent Infringement Nature of Suit: 830 Patent External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Boehringer Ingelheim
Medtronic
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.